Abstract
P-selectin on endothelial cell surfaces is central to impaired microvascular blood flow in sickle cell disease (SCD). Restoration of blood flow is expected to provide therapeutic benefit for SCD patients, whatever the mechanism of action of the treatment. Long-term oral administration of a P-selectin-blocking agent potentially improves blood flow and averts acute painful vaso-occlusive crises in patients with SCD. This review focuses on the pathophysiology of the impairment of microvascular blood flow in SCD with an emphasis on the role of P-selectin and summarizes the status of development of antiselectin therapies as a means of improving microvascular flow.
Original language | English (US) |
---|---|
Pages (from-to) | 323-339 |
Number of pages | 17 |
Journal | Hematology/Oncology Clinics of North America |
Volume | 28 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2014 |
Keywords
- Impaired blood flow in sickle cell disease
- Microvascular occlusion
- P-selectin
- Pentosan polysulfate sodium
- Sickle cell disease
- Sickle red cell adhesion
ASJC Scopus subject areas
- Hematology
- Oncology